tbuckley/cabot-search huggingface dataset:
BI-33 * BEVACIZUMAB-INDUCED HYPERTENSION IS A PREDICTIVE MARKER FOR IMPROVED OUTCOMES IN RECURRENT GLIOBLASTOMA
Authors: J. Zhong, A. Ali, A. Voloschin, Y. Liu, W. Curran, I. Crocker, H.-K. Shu
Journal: Neuro-Oncology (2014)

PURPOSE: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) approved for treatment of recurrent glioblastoma (GBM). Previous studies have demonstrated differential outcomes for patients treated with this agent for other tumors based on whether hypertension developed as a side effect. We conducted a single-institutional retrospective study analyzing survival outcomes for patients with recurrent GBM treated with bevacizumab based on whether patients developed drug-induced hypertension. PATIENTS AND METHODS: All GBM patients treated within Emory Healthcare from 2007-2012 were reviewed. 82 patients were identified that received bevacizumab for recurrent GBM and were included on study. Patients were classified as normotensive or hypertensive depending on whether hypertension developed secondary to therapy. Progression free survival (PFS) and overall survival (OS) were graphed by the Kaplan-Meier method and normotensive versus hypertensive groups were compared by log rank tests. Univariate and multivariate analysis were performed using the Cox proportional hazard method assessing for potential patient, treatment and tumor factors that may predict outcome. RESULTS: Median followup time was 7 months. Of the 82 recurrent GBM patients treated with bevacizumab, 30 developed drug-induced hypertension. Median time to development of hypertension was 21 days. Median PFS for the normotensive and hypertensive groups was 2.5 months (95% CI: 1.6-3.0) and 6.7 months (95% CI: 4.6-10.0), respectively (p <0.001). Median OS for the normotensive and hypertensive groups was 4.9 (95% CI: 4.4-6.8) and 11.7 (95% CI: 9.0- 20.5), respectively (p <0.001). Drug-induced hypertension was the only factor found to be significant on univariate analysis when evaluated for both PFS (HR: 0.24, 95% CI: 0.14-41) and OS (HR: 0.32, 95% CI: 0.19-0.53) endpoints (p <0.001). CONCLUSION: Patients with recurrent GBM who developed bevacizumab-induced hypertension demonstrated significantly better PFS and OS. Bevicizumab-induced hypertension may be a physiologic marker of outcome in recurrent GBM patients.
Tc-99m MIBI SPECT Correlated with Magnetic Resonance Imaging for Cardiac Evaluation of a Patient with Congenitally Corrected Transposition of the Great Arteries (L-TGA)
Authors: MATTHIAS SCHMIDT, PETER THEISSEN, DETLEF MOKA, EBERHARD VOTH, HEINZ-THEO SCHMITTER, HARALD SCHICHA
Journal: Clinical Nuclear Medicine (2001)

SCHMIDT, MATTHIAS M.D.; THEISSEN, PETER M.D.; MOKA, DETLEF M.D.; VOTH, EBERHARD M.D.; SCHMITTER, HEINZ-THEO M.D.; SCHICHA, HARALD M.D. Author Information
Hyperuricemia in Mongolism
Authors: Joel M. Kaufman, William M. O'Brien
Journal: New England Journal of Medicine (1967)

MONGOLISM has recently been investigated for disorders of purine metabolism. Although the numbers of patients studied is small, a correlation appears to exist between hyperuricemia and mongolism.Mertz, Fuller and Concon,1 in 25 patients with mongolism, two to twelve years of age, found a mean serum uric acid of 5.42 mg. as compared to 3.87 mg. per 100 ml. in mentally retarded controls without mongolism from the same institution. This seemed to be a highly significant increase (p less than 0.005). Earlier, Fuller, Luce and Mertz2 reported similar results in 40 older patients with mongolism. Appleton et al.3 discovered similar . . .
Care of older people in hospitals is unacceptable, says think tank
Authors: M. Limb
Journal: BMJ (2012)

Older people’s care often breaks down in hospitals, and these failures in continuity of care are “unacceptable,” says the King’s Fund.

Jocelyn Cornwell, who led an analysis for the health policy think tank, said many frail, older people in hospitals with multiple conditions were being let down by poor communication from frontline staff, inadequate coordination, and poor planning.

She said one of the most glaring findings was how often patients were being moved around inside hospitals for non-clinical reasons.

Ms Cornwell called for radical improvements in practices and attitudes, including a “new definition of excellence in care and a realisation that quality depends entirely on relationships between patients and people who look after them.”

She said, “It is time to turn the rhetoric of personalised care into the reality of everyday care and practice.” 

Ms …
514 IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGYLATED-INTERFERON-A (PIFN)
Authors: J.A. Holmes, T. Nguyen, D. Ratnam, N.M. Heerasing, J.V. Tehan, S. Bonanzinga, A. Dev, S.J. Bell, S. Pianko, K. Visvanathan, F. Rusli, W. Sievert, P.V. Desmond, S. Bowden, A.J. Thompson
Journal: Journal of Hepatology (2012)
Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction
Authors: Derek V. Exner, Daniel L. Dries, Michael J. Domanski, Jay N. Cohn
Journal: New England Journal of Medicine (2001)

Black patients with heart failure have a poorer prognosis than white patients, a difference that has not been adequately explained. Whether racial differences in the response to drug treatment contribute to differences in outcome is unclear. To address this issue, we pooled and analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials, two large, randomized trials comparing enalapril with placebo in patients with left ventricular dysfunction.
Indirect Cost Problems Branded "Systemic"
Authors: N. Volkers
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Indirect Cost Problems Branded “Systemic” Get access Nancy Volkers Nancy Volkers Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 5, 4 March 1992, Pages 295–296, https://doi.org/10.1093/jnci/84.5.295 Published: 04 March 1992
PTH-145 Investigation of Participant Responses and Implications for uptake following Spoilt Test Kits in the Welsh Bowel Cancer Screening Programme
Authors: H Beer, H Heard
Journal: Gut (2013)

<h3>Introduction</h3> Participants return kits to the Bowel Screening Wales (BSW) laboratory for testing. It is not possible to test some kits and these are spoilt. The BSW Laboratory has seen an increase in spoilt rate from 1.8% in Sep 2011 to 3.2% in Sep 2012, most related to a change in laboratory procedure to reject samples because identifiers written on the test kit did not match details held on the BSW Information Management System. BSW analysed the effect this change in policy may have had on response rates longer term within the programme in the context of a decreasing uptake rate (currently at 53%). This was based on the hypothesis that not all participants might complete a second test kit. <h3>Methods</h3> Participants were recorded as final non responders if no test kit has been received within six months of the initial invitation. Participants with a spoilt result validated from Oct 2008 to May 2012 were included in the analysis. <h3>Results</h3> During the time period 8400 test kits were spoilt by the laboratory, 78% returned the test kit that was sent with the spoilt result and 80% returned another test kit sent in the same invitation episode. 80% returned FOB (Faecal Occult Blood test) kits and 90% FIT (Faecal Immunochemical Test) kits sent following an equivocal FOB result. If participants did respond, it was usually received within 4 weeks (70%), with another 6% returning their kit within 4–8 weeks later and 4% sending in their kit more than two months later. The helpline received numerous calls from participants who were disappointed to have had their kit spoilt because of identity reasons. This may have potentially resulted in a decrease in motivation on part of the participant. For those participants who did not send another kit back during the same episode (20%), to date only half have been re-invited as part of their next routine recall allowing six months follow up. Of these participants re-invited in a new episode 74% have not responded, (74% for FOB kits and 67% for FIT kits). Figures for spoilt FOB were similar for males and females, with younger participants less like to respond. Figures for FIT kits show men more likely to return their later kit (this may need to be interpreted with caution in view of the limited sample size in this group). <h3>Conclusion</h3> 20% of participants who respond and have a spoilt test result do not respond to another kit issued in the same invitation episode. These participants appear less likely to attend screening during the next invitation episode, 26% responded (allowing six months follow up). With 5000 spoilt test results issued per annum, 260 participants may not take part in the programme again. We suggest that further studies may help towards directing efforts for increased uptake in this group. <h3>Disclosure of Interest</h3> None Declared.
Prévention de la sténose oesophagienne après dissection sous-muqueuse endoscopique circonférentielle: évaluation de la membrane amniotique humaine
Authors: M Barret, M Camus, C Pratico, M Jarraya, F Beuvon, S Chaussade, F Batteux, F Prat
Journal: Endoscopy (2012)

La prise en charge de l'endobrachyoesophage se heurte à une morbidité importante de la chirurgie oesophagienne. Le développement de techniques de résections muqueuses ou sous-muqueuses endoscopiques étendues fait émerger la problématique de la sténose oesophagienne cicatricielle et de sa prévention. La membrane amniotique humaine (MAH) est un produit disponible et largement utilisé chez l'Homme -en ophtalmologie essentiellementpour ses propriétés cicatrisantes, anti-inflammatoires et anti-fibrosantes. Nous avons étudié l'intérêt de la MAH dans la prévention de la sténose oesophagienne post-endoscopique sur un modèle porcin.
1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA
Authors: E. Ogawa, N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, Y. Tanabe, T. Satoh, T. Maruyama, M. Nakamuta, K. Kotoh, K. Azuma, K. Dohmen, S. Shimoda, J. Hayashi
Journal: Journal of Hepatology (2012)
THU0049 Uc-Mscs Inhibit Both T Cell Apoptosis and Autophagy in Patients with Systemic Lupus Erythematosus
Authors: J. Chen, X. Feng, L. Sun
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> T cells from SLE patients have higher spontaneous apoptotic rate than that from healthy donors. The appearance of nucleosomes from these apoptotic cells in circulation may induce the production of autoantibodies and subsequently cause organ damage. Meanwhile, an aberrant autophagy of T cells from SLE patients has been observed. <h3>Objectives</h3> To investigate the relationship between apoptosis and autophagy of T cells from SLE patients, and to find out whether umbilical cord derived mesenchymal stem cells (UC-MSCs), previously shown to inhibit autoantibody production after in vivo transplantation, act through the regulation of T cell apoptosis and autophagy. <h3>Methods</h3> Peripheral blood mononuclear cells (PBMCs) were isolated from SLE patients and healthy donors, and then CD3+T cells were purified with microbeads and cultured under stimulation with anti-CD3/28 antibodies in the presence or absence of autophagy inhibitor 3-MA (5mM for 6h) or activator rapamycin (50nM for 48h). To find out the effect of MSCs on T cell autophagy, UC-MSCs were cocultured with T cells at the ratio of 1:10. Apoptosis and autophagy level were measured by flow cytometry with the detection of Annexin V and LC3IIB respectively. Anti-dsDNA antibodies were quantificated by ELISA. <h3>Results</h3> T cells from SLE patients had high apoptotic level (0.71±0.13% vs. 1.78±0.32% for CD4+T, <i>p</i>=0.05; 1.82±0.23% vs. 3.58±0.32% for CD8+T, <i>p</i>&lt;0.01) and increased autophagy rate (3.58±0.07% vs. 5.25±0.22% for CD4+T; 5.01±0.09% vs. 7.52±0.26% for CD8+T, both <i>p</i>&lt;0.001) compared with those from normal controls. The apoptotic rate of CD8+T cells was significantly correlated with serum anti-dsDNA antibody levels (r=0.755, <i>p&lt;</i>0.05). Inhibition of autophagy with 3-MA decreased the apoptotic rate of T cells (32.1±9.4% vs. 20.4±5.2%, <i>p</i>&lt;0.05), whereas activation of autophagy with rapamycin increased the apoptotic rate (33.1±10.0% vs. 65.3±10.1%, <i>p</i>&lt;0.001). UC-MSCs could decrease both T cell autophagy (36.4±6.3 vs. 22.5±2.4 for CD4+T; 39.2±5.4 vs. 27.2±1.9 for CD8+T, both <i>p</i>&lt;0.05) and T cell apoptosis (49.1±5.7% vs. 22.2±2.6% for CD4+T; 53.2±2.3% vs. 23.3±2.4% for CD8+T, both <i>p</i>&lt;0.05). <h3>Conclusions</h3> T cells from SLE patients have high spontaneous apoptotic rate, which is related to the aberrant autophagy. UC-MSCs may inhibit T cell apoptosis through the modulation of autophagy. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2419
Abstract 2280: Endothelin axis in bladder cancer metastasis
Authors: Neveen A. Said, Dan Theodorescu
Journal: Cancer Research (2010)

Abstract In bladder cancer, recurrence after surgical intervention for muscle invasive disease is problematic as nearly half of patients harbor occult distant metastases, mainly in the lungs, with poor 5-year survival rate. Our prior work has indicated that RhoGDI2 reduces tumor Endothelin 1 (ET-1) secretion and this may contribute to its metastasis suppressor function, however how the endothelin axis acts to promote lung metastasis is unclear. We have found from gene expression profiling of human bladder tumors that high ET-1 expression was correlated with poor survival. Here we also identify ET-1 as a novel mediator of bidirectional cross talk between tumor cells and inflammatory macrophages. Tumor-derived endothelin, through its cognate endothelin receptor A (ETAR) exerts autocrine and paracrine effects on tumor cells and macrophages, significantly inducing its own production, by both cell types, concomitant with triggering an early inflammatory response in the lungs, which progressively increases till development of lung metastases. Abrogation of ET-1/ETAR axis by knock down tumor cell ET-1 by short hairpin RNA (shRNA) or systemic administration of ETAR blocker (ZD4054) significantly suppressed the development and the progression of this lung inflammatory response, and decreased the development of microscopic and macroscopic lung metastases, together with improvement of animal survival. In vitro, genetic manipulation of ET-1, ETAR and ETBR in bladder cancer cell lines co-cultured with macrophages revealed that ET-1 augments the inflammatory response through activation of transcriptional factors NFκB and AP-1, key orchestrators of inflammation, in both cancer cells and macrophages. The reciprocal activation of both transcriptional factors was mediated by ET-1/ETAR axis in cancer cells, whereas in macrophages it was mediated by ET-1/ETAR and ETBR axis. These findings highlight a molecular mechanism that can be pharmacologically manipulated to enhance the efficacy of current adjuvant approaches to muscle invasive bladder cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2280.
Dyslexia — Is It a Disease?
Authors: Peter B. Rosenberger
Journal: New England Journal of Medicine (1992)

NEARLY a century has passed since the first published observation that some otherwise normally intelligent children have specific difficulty learning to read. The intervening years have seen both an intense search for the mechanism of this disorder and an ongoing debate about whether it exists. There have been a number of developments in this field since I last discussed these issues.1 The disorder was first termed "congenital word blindness" by British ophthalmologists, and for several decades it was assumed to be primarily visual. Then, in the 1930s, the American neurologist Samuel Orton called attention to the frequent association between reading . . .
Abstract P6-08-08: Nucleolin as an Intracellular Transporter of Hsp72
Authors: A Asea, A Pradeep, P Kaur, P Bempong, S. Lillard
Journal: Cancer Research (2010)

Abstract Background: Our previous studies demonstrated that thermal stress induces the release of Hsp72 from cells by a mechanism independent of the classical protein transport pathway. However, the exact mechanism by which Hsp72, a leaderless protein, gains access to the extracellular milieu remains unknown. Materials and Methods: In this study we use flow cytometry to measure the expression of surface bound Hsp72 in THP1 human monocytic cells. Sucrose gradient ultracentrifugation was also used to isolate and recover intracellular fractions. Western blot analysis was used to probe for intracellular fractions expressing Hsp72, Hsp90, Grp96, CAP2, TLR2, 4, or 7. Baculovirus expression vector system (BEVS) was used to generate highly purified endotoxin free Hsp72. Plasma membrane cross-linking assay was used to identify the interacting proteins of Hsp72 on cell plasma membrane. Laser scanning confocal microscopy was used to demonstrate the plasma membrane localization and internalization of Hsp72 with other interacting proteins. In-gel digestion and LC-mass spectrometry was used to identify unique proteins colocalizing with Hsp72. Results: The data presented in this study suggest that Hsp72 trafficking within the cell and its release is assisted in part by, nucleolin. We further demonstrate that within 60 minutes after first exposure of cells to heat shock treatment, plasma membrane bound Hsp72 is internalized and redistributed into cytosolic compartments. Inhibition of active cell transport by pre-treatment of cells with Cytochalasin B completely abrogated Hsp72 redistribution from the plasma membrane into the cytosol. Cross-linking of plasma membrane bound proteins with Hsp72 followed by Western blot analysis, in-gel digestion and LC-MS/MS analysis revealed seven interacting partners with Hsp72, including Hsp90, nucleolin, gp96, CAP2, TLR2, 4 and 7. Transfection of cells with nucleolin-siRNA completely inhibited baseline and heat shock-induced Hsp72 release. Discussion: Our study for the first time demonstrates that the plasma membrane acts as a reservoir for Hsp72 and confirms that nucleolin plays an important role in Hsp72 trafficking and release. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-08-08.
Traumatic Pseudodiverticulums of the Pharynx in Newborn Infants
Authors: Bertram R. Girdany, William K. Sieber, Mazloum Z. Osman
Journal: New England Journal of Medicine (1969)

Perforation of the posterior pharyngeal wall during or immediately after delivery produced symptoms of esophageal atresia and traumatic diverticulums of the pharynx in two newborn infants. Nasogastric tubes could not be passed probably because of cricopharyngeal spasm. Although traumatic pseudodiverticulums of the pharynx in newborn infants have not previously been described in the American literature, it is likely that the condition is not rare.
FDG PET/CT Findings in Abdominal Fat Necrosis After Treatment for Lymphoma
Authors: Julien Dubreuil, Aurélie Moreau, Clémentine Sarkozy, Alexandra Traverse-Glehen, Andrea Skanjeti, Gilles Salles, Francesco Giammarile
Journal: Clinical Nuclear Medicine (2016)

FDG PET/CT is now validated in non-Hodgkin lymphoma for response assessment in interim and posttreatment lymphoma. We report the case of a 62-year-old man followed by FDG PET/CT for a diffuse large B-cell lymphoma, with initial stage III. The interim FDG PET/CT examination concluded in complete metabolic and morphological response of subdiaphragmatic lymphadenopathy but a persistent abnormal subdiaphragmatic uptake (SUVmax at 9 and Deauville 5-point scale at 5). Therefore, an abdominal biopsy of the corresponding nodules was conducted with a final diagnosis of diffuse fat necrosis.
An Unusual Localization of Extramedullary Hematopoiesis
Authors: ERKAN VARDARELI, EMRE ENTOK, ILKNUR AK, HIKMET BAYHAN
Journal: Clinical Nuclear Medicine (1996)

A 37-year-old man with a history of thalassemia intermedia diagnosed 20 years earlier had fatigue, weakness, and a yellowish discoloration of the skin and sclera. On physical examination he was noted to have only mild hepatomegaly. Cirrhosis and hemosiderosis were diagnosed by liver biopsy. Tc-99m SC bone marrow scintigraphy and SPECT imaging demonstrated an unusual accumulation of tracer in the pelvis mimicking the bladder. Two months later, In-111 demonstrated an extramedullary bone marrow site at the same location. Diagnosis was confirmed by CT scan and CT guided needle biopsy.
Abstract B31: Pharmacogenetics and pharmacoepigenetics of childhood acute lymphoblastic leukemia
Authors: Elixabet Lopez-Lopez, Idoia Martin-Guerrero, Javier Ballesteros, Javier Uriz, Nagore Garcia de Andoin, M. Angeles Piñan, Pura Garcia-Miguel, Aurora Navajas, Africa Garcia-Orad
Journal: Clinical Cancer Research (2010)

Abstract Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, and still an important cause of cancer-related death in children. Although the introduction of treatment protocols has improved survival, inter-individual differences in drug responses are an important cause of resistance to treatment and adverse drug reactions. These differences can be due to different factors, including genetic polymorphisms and epigenetic variations. The aim of the present study was to determine if there was a correlation between genetic and epigenetic variation and toxicity and/or outcome during therapy in paediatric ALL patients treated according to the LAL/SHOP protocol (high-dose methotrexate [MTX] and 6-mercaptopurine [6-MP]). We analyzed genetic polymorphisms and epigenetic variations of 12 genes in paediatric ALL patients: 6 genes of the MTX pathway (MTHFR, TYMS, SHMT1, RFC1, ABCB1 and ABCG2), 1 gene of the 6-MP pathway (TPMT) and 5 genes involved in xenobiotic detoxification (CYP1A1, NQO1 and the GSTs GSTM1, GSTT1 and GSTP1). Several associations were found between polymorphisms and clinical parameters, such as that of the MTHFR C677T and A1298C polymorphisms and hepatotoxicity and gastrointestinal toxicity respectively. Our results indicate that polymorphisms in the MTX pathway may be useful as predictors of toxicity and outcome in ALL patients. This project was supported by RTICS (RD/06/0020/0048) and Basque Government (IT-463-07 and 2006111015). Citation Information: Clin Cancer Res 2010;16(7 Suppl):B31
Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors: Johan Thörlén, Olle Ringdén, Jennifer Le Rademacher, Minoo Battiwalla, Junfang Chen, Vincent T. Ho, Partow Kebriaei, Carolyn A. Keever-Taylor, Tamila L. Kindwall-Keller, Hillard M. Lazarus, Mary J. Laughlin, Michael Lill, Tracey A. O’Brien, Miguel Angel Perales, Vanderson Rocha, Bipin N. Savani, David Szwajcer, David Valcarcel, Mary Eapen
Journal: Blood (2013)